Crestor and Opioids (Oxycodone, Hydrocodone, Tramadol): What Clinicians and Patients Should Know

Why This Combination Comes Up So Often

Roughly 38 million Americans take a statin, and opioid prescriptions, though declining from their 2012 peak, still numbered 142.8 million dispensed in 2020 according to CDC surveillance data. Overlap is inevitable. A patient recovering from surgery, managing chronic back pain, or dealing with cancer-related pain may already be taking rosuvastatin for cardiovascular risk reduction.

The Clinical Scenario

Prescribers searching for this interaction are typically asking one narrow question: will adding oxycodone 5 mg every 6 hours for post-operative pain interfere with my patient's Crestor 20 mg? The short answer is no, not through any direct metabolic collision. But "no major interaction" does not mean "nothing to watch." The sections below break down exactly where the risks do and do not exist.

Why Rosuvastatin Is Different from Other Statins

Rosuvastatin stands apart in the statin class. Unlike atorvastatin or simvastatin, which are extensively metabolized by CYP3A4, rosuvastatin undergoes minimal hepatic CYP metabolism [1]. Roughly 10% of rosuvastatin clearance involves CYP2C9, with the rest handled by direct hepatic uptake via OATP1B1 and OATP1B3 transporters followed by biliary and renal excretion [2]. This pharmacokinetic profile is precisely what makes rosuvastatin less interaction-prone with opioids than its CYP3A4-dependent cousins.

Pharmacokinetic Analysis: Rosuvastatin vs. Each Opioid

The interaction potential for any drug pair depends on shared metabolic enzymes, transporter competition, and protein-binding displacement. Rosuvastatin's unique metabolism means each opioid must be evaluated individually.

Rosuvastatin and Oxycodone

Oxycodone is primarily metabolized by CYP3A4 to noroxycodone and by CYP2D6 to oxymorphone [3]. Rosuvastatin does not inhibit or induce CYP3A4 or CYP2D6. The FDA-approved label for rosuvastatin (Crestor) lists no interaction with opioid analgesics, and the oxycodone label does not flag statins as interacting drugs [4]. From a pure enzyme-competition standpoint, these two drugs occupy different metabolic lanes entirely.

Protein binding also does not create a conflict. Rosuvastatin is approximately 88% bound to plasma proteins (primarily albumin), while oxycodone is only 45% protein-bound [3]. Displacement interactions require both drugs to be highly bound (above 90%) to the same protein. That threshold is not met here.

Rosuvastatin and Hydrocodone

Hydrocodone follows a similar CYP3A4/CYP2D6 metabolic pathway. CYP3A4 converts hydrocodone to norhydrocodone, while CYP2D6 produces hydromorphone, the more potent metabolite [5]. Because rosuvastatin has negligible CYP3A4 or CYP2D6 activity, co-administration does not alter hydrocodone's plasma levels or its conversion to active metabolites.

One indirect consideration: hydrocodone combination products (e.g., hydrocodone/acetaminophen) introduce acetaminophen's hepatic burden. In a patient already on rosuvastatin, stacking acetaminophen at maximum daily doses (3,000 to 4,000 mg) adds hepatotoxic stress. The American College of Gastroenterology recommends keeping acetaminophen below 2,000 mg/day in patients with any liver concern [6]. This is not a rosuvastatin-hydrocodone interaction per se, but it matters in practice.

Rosuvastatin and Tramadol

Tramadol is the most pharmacologically complex of the three. It is metabolized by CYP2D6 to O-desmethyltramadol (M1), the metabolite responsible for mu-opioid receptor activity, and by CYP3A4 to N-desmethyltramadol [7]. Again, no direct CYP competition with rosuvastatin exists.

The concern with tramadol is pharmacodynamic, not pharmacokinetic. Tramadol inhibits serotonin and norepinephrine reuptake, and it lowers the seizure threshold. Statins, in rare post-marketing reports, have also been associated with seizure-like events, though a causal link remains unestablished [8]. The FDA's adverse event reporting system (FAERS) contains case reports for rosuvastatin-associated seizures, but the signal is weak and confounded. If a patient has a seizure history, the tramadol-statin pairing warrants explicit documentation and discussion, not because of a proven synergistic risk, but because both carry independent (if rare) seizure-related signals.

Transporter-Level Interactions: The BCRP and OATP Question

Rosuvastatin's clinically significant interactions occur at the transporter level, not the CYP level. The breast cancer resistance protein (BCRP, encoded by ABCG2) and organic anion-transporting polypeptides OATP1B1/1B3 control rosuvastatin's hepatic uptake and intestinal absorption [2].

Which Drugs Actually Inhibit These Transporters?

Known BCRP inhibitors that raise rosuvastatin levels include cyclosporine (which increased rosuvastatin AUC 7.1-fold in a pharmacokinetic study), certain HIV protease inhibitors (lopinavir/ritonavir increased AUC 2.1-fold), and gemfibrozil [1]. Oxycodone, hydrocodone, and tramadol have not been identified as BCRP or OATP1B1 inhibitors in any published in vitro or clinical study. The Crestor prescribing information does not list any opioid among its transporter-mediated interaction concerns [1].

CYP2D6 Polymorphisms and Indirect Effects

One layer of complexity: CYP2D6 poor metabolizers (roughly 6 to 10% of Caucasians) will have altered opioid metabolism but unchanged rosuvastatin handling [9]. A CYP2D6 poor metabolizer taking tramadol gets less M1 (the active opioid metabolite), potentially leading to inadequate analgesia and a clinician's decision to switch to oxycodone or hydrocodone. None of these CYP2D6-driven prescribing changes affect rosuvastatin levels, but they change the opioid side of the equation in ways that matter clinically.

Pharmacodynamic Overlap: What to Actually Monitor

The absence of a pharmacokinetic interaction does not eliminate all concerns. Several pharmacodynamic overlaps deserve attention.

Hepatic Stress

Rosuvastatin carries a class warning for hepatotoxicity. The JUPITER trial (N=17,802) found ALT elevations above three times the upper limit of normal in 0.3% of rosuvastatin-treated patients versus 0.2% on placebo [10]. Opioids, particularly when formulated with acetaminophen, add hepatic burden. For patients on chronic opioid therapy alongside rosuvastatin, the 2018 American Association of Clinical Endocrinology (AACE) lipid guidelines recommend baseline hepatic panel and repeat testing if symptoms develop [11].

Gastrointestinal Motility

Opioids slow GI transit. That is their best-known non-analgesic effect. Opioid-induced constipation (OIC) affects 40 to 80% of patients on chronic opioid therapy [12]. Rosuvastatin is absorbed in the proximal small intestine, reaching peak plasma concentration in 3 to 5 hours [1]. Severe OIC could theoretically alter transit time enough to shift rosuvastatin absorption, though no clinical study has measured this effect directly.

For patients reporting significant OIC, separating rosuvastatin dosing from opioid dosing by at least 2 hours and monitoring LDL response at 6 to 8 weeks is a reasonable precaution.

Myopathy Risk in Context

Statin-associated muscle symptoms (SAMS) occur in 7 to 29% of statin users depending on the definition used, per a 2015 European Atherosclerosis Society consensus panel [13]. Opioids can mask musculoskeletal pain, potentially delaying recognition of true statin myopathy. If a patient on both rosuvastatin and chronic opioids reports new muscle pain after opioid dose reduction or discontinuation, the differential should include unmasked SAMS that were previously analgesically suppressed.

"Clinicians should reassess muscle symptoms whenever opioid therapy is tapered, because analgesic withdrawal can unmask pre-existing statin myopathy that was previously pain-controlled," noted a 2022 review in the European Heart Journal on statin side-effect management [14].

Severity Ratings Across Major DDI Databases

Drug interaction databases do not all use the same classification system. Here is how the rosuvastatin-opioid combination is rated:

| Database | Rosuvastatin + Oxycodone | Rosuvastatin + Hydrocodone | Rosuvastatin + Tramadol | |---|---|---|---| | Lexicomp | No interaction listed | No interaction listed | No interaction listed | | Micromedex | No interaction listed | No interaction listed | No interaction listed | | FDA Label (Crestor) | Not mentioned | Not mentioned | Not mentioned | | Clinical Pharmacology | No interaction | No interaction | Monitor (hepatic, theoretical) |

The absence of a listing in Lexicomp, Micromedex, and the FDA label is itself informative. These databases flag interactions down to "minor" severity. When a pair does not appear at all, the pharmacokinetic evidence for interaction is essentially nonexistent.

Dose Adjustment Guidance

No dose adjustment is required for rosuvastatin when adding oxycodone, hydrocodone, or tramadol. No dose adjustment is required for any of these opioids when adding rosuvastatin. This guidance applies across the full rosuvastatin dose range (5 mg to 40 mg daily) and standard opioid dosing.

When Adjustments Might Be Considered Anyway

Three scenarios warrant extra attention despite the lack of a formal interaction:

1. Renal impairment (eGFR <30 mL/min/1.73m²): Rosuvastatin's starting dose is capped at 5 mg in severe renal impairment [1]. Opioid metabolites (particularly oxymorphone from oxycodone and hydromorphone from hydrocodone) also accumulate in renal failure. Both drugs need independent dose reduction, not because of an interaction, but because a shared clearance bottleneck (the kidney) slows elimination of both.

2. CYP2D6 ultra-rapid metabolizers on tramadol: These patients produce excess M1 metabolite, increasing opioid toxicity risk. This has nothing to do with rosuvastatin, but it is a prescribing trap that surfaces when tramadol is added to any regimen.

3. Patients of East Asian descent: The Crestor label recommends a starting dose of 5 mg in Asian patients due to a roughly 2-fold increase in rosuvastatin exposure related to ABCG2 polymorphisms (c.421C>A) that are more prevalent in East Asian populations [1]. Opioid dosing is unaffected by this polymorphism.

Patient Counseling Points

Patients asking whether they can take their Crestor with a prescribed opioid deserve a direct answer: yes, these medications can be taken together. Beyond that baseline reassurance, three counseling points matter.

Timing and Administration

Take rosuvastatin at the same time each day, with or without food. Opioids can be taken on their prescribed schedule regardless of rosuvastatin timing. If severe constipation develops from the opioid, tell your prescriber, because GI slowdown could affect how well any oral medication is absorbed.

Symptom Reporting

Report unexplained muscle pain, tenderness, or weakness to your prescriber. This is standard statin counseling, but it becomes more important when opioids are involved because opioids can mask the early warning signs of myopathy. If you are tapering off an opioid and new muscle symptoms appear, that timing is clinically relevant.

Alcohol and the Liver

Both rosuvastatin and opioids stress the liver. Alcohol magnifies that burden. The Endocrine Society's clinical practice guidelines recommend limiting alcohol intake to fewer than two drinks daily for patients on statin therapy [15]. Opioid prescribing guidelines from the CDC similarly flag alcohol as a respiratory-depression risk multiplier [16]. The combined message: minimize alcohol while on both medications.

Comparison with Other Statins

Rosuvastatin is the safest statin to combine with opioids from a metabolic interaction standpoint. For comparison:

• Simvastatin is a CYP3A4 substrate. Oxycodone and hydrocodone are CYP3A4 substrates. Co-administration creates competitive inhibition potential, and simvastatin already carries the highest myopathy risk in the statin class at the 80 mg dose [17].
• Atorvastatin is also CYP3A4-metabolized, though its interaction risk with opioids is lower than simvastatin's because atorvastatin's metabolites retain activity even when parent-drug levels shift [18].
• Rosuvastatin and pravastatin are the two statins with minimal CYP3A4 involvement. Both are preferred in patients on complex multi-drug regimens, per the 2018 AHA/ACC cholesterol guideline [19].

"When patients require medications with significant CYP3A4 involvement, rosuvastatin or pravastatin should be considered as alternatives to minimize pharmacokinetic drug interactions," states the 2018 AHA/ACC multi-society guideline on blood cholesterol management [19].

Special Populations

Older Adults (Age 65+)

Polypharmacy peaks in older adults. A patient on rosuvastatin, hydrocodone for osteoarthritis pain, a proton pump inhibitor, and an antihypertensive is common. Rosuvastatin pharmacokinetics show a modest increase in AUC (approximately 30%) in patients aged 65 and older [1], but this does not create a new interaction with opioids. The concern in this population is additive: fall risk from opioid sedation, statin myopathy mimicking frailty, and renal decline affecting both drug classes.

Patients with Hepatic Impairment

Rosuvastatin is contraindicated in active liver disease or unexplained persistent transaminase elevations [1]. In patients with Child-Pugh A or B cirrhosis, rosuvastatin exposure increases roughly 3-fold [1]. Opioid metabolism is also impaired in hepatic dysfunction, with prolonged half-lives and increased sensitivity. Both drugs require independent dose reduction in this population.

Chronic Pain Patients on Long-Term Opioid Therapy

Patients on stable, long-term opioid therapy for chronic non-cancer pain often have metabolic syndrome features (central obesity, insulin resistance, dyslipidemia) that make statin therapy a guideline-directed intervention. A 2019 cohort study in JAMA Internal Medicine (N=48,852) found that chronic opioid users had a 35% higher rate of cardiovascular events compared to matched non-users [20]. Withholding or delaying statin therapy because of a theoretical opioid interaction would be clinically counterproductive.

Bottom Line: A Low-Risk Combination That Still Requires Clinical Awareness

The rosuvastatin-opioid pairing does not trigger a pharmacokinetic interaction through CYP enzymes, transporters, or protein binding. Major DDI databases do not flag it. No dose adjustments are needed. The real clinical task is monitoring hepatic function when acetaminophen-containing opioid formulations are used, reassessing muscle symptoms during opioid tapers, and managing GI motility changes that could indirectly affect statin absorption. For patients on rosuvastatin 10 to 20 mg daily, baseline ALT and a repeat check at 12 weeks after adding chronic opioid therapy provides reasonable safety surveillance without over-testing.